http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 16:01:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54438658&amp;newsitemid=20260304374355&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=0b22d308755e22d092f5036cd132012d" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 100,000 shares of common stock to new non-executive employees as a material inducement to http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html Wed, 04 Mar 2026 16:01:00 +0000 FBRX O.21049479 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54438658&amp;newsitemid=20260304374355&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=0b22d308755e22d092f5036cd132012d" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 100,000 shares of common stock to new non-executive employees as a material inducement to http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html Wed, 04 Mar 2026 16:01:00 +0000 FBRX O.21049479 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54438658&amp;newsitemid=20260304374355&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=0b22d308755e22d092f5036cd132012d" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 100,000 shares of common stock to new non-executive employees as a material inducement to http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html Wed, 04 Mar 2026 16:01:00 +0000 FBRX O.21049479 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54438658&amp;newsitemid=20260304374355&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=0b22d308755e22d092f5036cd132012d" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. </p><p> In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase an aggregate total of 100,000 shares of common stock to new non-executive employees as a material inducement to http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+Reports+Inducement+Grants+Under+NASDAQ+Listing+Rules/26110785.html Wed, 04 Mar 2026 16:01:00 +0000 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26014067.html si-local-file:///var/storage/secattach/20260217/26014067.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26014067.html Tue, 17 Feb 2026 16:37:00 +0000 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26014067.html si-local-file:///var/storage/secattach/20260217/26014067.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+JANUS+HENDERSON+GROUP+PLC/26014067.html Tue, 17 Feb 2026 16:37:00 +0000 FBRX O.21049479 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Press+Releases/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html <p> DALLAS--(BUSINESS WIRE)-- Forte Biosciences, Inc. (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=54421154&amp;newsitemid=20260209147037&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=b27b0580a22eb377930355fb74d9b2e4" shape="rect">www.fortebiorx.com</a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. </p><p> Forte’s CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. </p><p> Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will be presenting at the TD Cowen 46th Annual Healthcare Conference hosted at the Boston Marriot Copley Place in Boston, MA. </p><p> March 10-12, Dr. http://www.streetinsider.com/Business+Wire/Forte+Biosciences%2C+Inc.+to+Present+at+Upcoming+Investor+Meetings/25967888.html Mon, 09 Feb 2026 16:01:00 +0000 A.50100012 FBRX O.07579093 O.21049479 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/25918222.html si-local-file:///var/storage/secattach/20260129/25918222.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/25918222.html Thu, 29 Jan 2026 19:58:00 +0000 FBRX O.21049479 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/25918222.html si-local-file:///var/storage/secattach/20260129/25918222.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Forte+Biosciences%2C+Inc.++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/25918222.html Thu, 29 Jan 2026 19:58:00 +0000 FBRX O.21049479